BRAF基因与非小细胞肺癌的分子靶向治疗

doi:10.3760/cma.j.issn.1673-422X.2016.08.016

摘要/Abstract

摘要： BRAF基因是一个驱动基因，在肿瘤的发生发展中扮演重要角色，也是治疗非小细胞肺癌（NSCLC）的一个有效靶点，研究显示BRAF抑制剂在BRAF突变的NSCLC中取得肯定疗效。尽管BRAF抑制剂会产生耐药性，但其耐药机制及治疗策略正在不断探索中，了解BRAF基因的临床病理特征及其抑制剂的研究进展对NSCLC的个体化治疗十分重要。

关键词: 癌, 非小细胞肺, 治疗, BRAF基因

Abstract: B-Raf kinase (BRAF) gene is a driver mutation, and is an effective target in the treatment of nonsmall cell lung cancer （NSCLC）. Studies have shown that BRAF inhibitors are effective for treatment of NSCLC with BRAF mutant. It is important to understand the clinicopathologic features and the research progress of BRAF inhibitors for the individual treatment of NSCLC.

Key words: Carcinoma, non-small-cell lung, Therapy, BRAF gene

康晓艳,屈丽岩,宋霞. BRAF基因与非小细胞肺癌的分子靶向治疗[J]. 国际肿瘤学杂志, 2016, 43(8): 625-627.

Kang Xiaoyan， Qu Liyan, Song Xia. BRAF and targeted treatment for non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(8): 625-627.

参考文献

［1］黄志敏, 吴一龙. 非小细胞肺癌的BRAF基因突变及其临床意义［J］. 中国肺癌杂志, 2012, 15(3): 183-186. DOI： 10.3779/j.issn.1009-3419.2012.03.09. ［2］ Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5 125 Chinese cohorts［J］. Br J Cancer, 2014, 110(11): 2812-2820. DOI: 10.1038/bjc.2014.210. ［3］ Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer［J］. Clin Cancer Res, 2013, 19(16): 4532-4540. DOI: 10.1158/10780432.CCR-13-0657. ［4］ Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small cell lung cancer harboring BRAF mutations［J］. J Clin Oncol, 2011, 29(26): 3574-3579. DOI: 10.1200/JCO.2011.35.9638. ［5］ Chen D, Zhang LQ, Huang IF, et al. BRAF mutations in patients with non-small cell lung cancer, a systematic review and metaanalysis［J］. PLoS One, 2014, 9(6): e101354.DOI: 10.1371/journal.pone.0101354. ［6］ Brustugun OT, Khattak AM, Tromborg AK, et al. BRAFmutations in non-small cell lung cancer［J］. Lung Cancer, 2014, 84(1): 36-38.DOI: 10.1016/j.lungcan.2014.01.023. ［7］ Alrifai D, Popat S, Ahmed M, et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations［J］. Lung Cancer, 2013, 80(3): 339-340.DOI: 10.1016/j.lungcan.2013.02.002. ［8］ Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1［J］. Proc Natl Acad Sci USA, 2012, 109(31): E2127-2133. DOI: 10.1073/pnas.1203530109. ［9］ Robinson S, O′Shaughnessy J, CL C, et al. BRAF V600Emutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib［J］. Lung Cancer, 2014, 85(2): 326-330.DOI: 10.1016/j.lungcan.2014.05.009. ［10］ Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAFmutant lung cancer: results from the european EURAF cohort［J］. J Thorac Oncol, 2015, 10(10): 1451-1457.DOI: 10.1097/JTO.0000000000000625. ［11］Gibney G, Zager J. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies［J］. Expert Opin Drug Metab Toxicol, 2013, 9(7): 893-899.DOI: 10.1517/17425255.2013.794220. ［12］Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patient with BRAF V600Emutant advanced nonsmall cell lung cancer(NSCLC): a multicenter, open-label, phase Ⅱ trial(BRF113928)［J］. Ann Oncol, 2014, 25(suppl 4): v1-v41. ［13］Schmid S, Siano M, Joerger M, et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600Emutant bronchial adenocarcinoma［J］. Lung Cancer, 2015, 87(1): 85-87.DOI: 10.1016/j.lungcan.2014.11.008. ［14］Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer［J］. Cancer Discov, 2011, 1(1): 4453. DOI: 10.1158/21598274.CD-10-0010. ［15］Sereno M, Moreno V, Moreno Rubio J, et al. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation［J］. Anticancer Drugs, 2015, 26(9):1004-1007.DOI: 10.1097/CAD.0000000000000277. ［16］Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAFmutant non-small cell lung cancer［J］. J Thorac Oncol, 2013, 8(5): e41-42. DOI: 0.1097/JTO.0b013e31828bb1b3 ［17］Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy［J］. Br J Cancer, 2010, 102(12): 1724-1730.DOI: 10.1038/sj.bjc.6605714. ［18］Joshi M, Rice SJ, Liu X, et al. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer［J］. PLoS One, 2015, 10(2): e0118210.DOI: 10.1371/journal.pone.0118210. ［19］耿睿, 潘莉, 宋霞. 程序性死亡配体-1及其抑制剂在非小细胞肺癌中的研究进展［J］. 国际肿瘤学杂志, 2015, 42(8): 628-630. DOI： 103760/cma.j.issn.1673422X.2015.08.019

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[5]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[6]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[7]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[8]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[9]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[10]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[11]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[12]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[13]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[14]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[15]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.